Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2

Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds

Tata Chemicals Europe to invest Rs. 655 crore on expansion of pharmaceutical grade sodium bicarbonate capacity

Construction of the plant will commence in 2025 with first production expected to be in 2027

Aurobindo Pharma Q2 FY25 net profit up 8.6% at Rs. 817 Cr

Growth markets revenue increased by 44 YoY to Rs. 812 crore

Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr

For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore

Orchid Pharma Q2 FY25 PAT up 26% YoY driven by strategic initiatives for market expansion

Emcure Pharmaceuticals posts Q2 FY25 consolidated PAT at Rs. 194.57 Cr

Emcure Pharmaceuticals has reported total income of Rs. 2,037.63 crores during the period ended September 30, 2024

JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr

JB’s domestic business continued to out-perform the market with all our major brands posting strong growth

Kwality Pharma received approval for Leuprorelin Acetate for injectable suspension from Greece

Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr

US Generics grew 5% to Rs. 467 Crores for the quarter

Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr

Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.